

# Paul Gow

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10380739/publications.pdf>

Version: 2024-02-01

23  
papers

506  
citations

759233

12  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

876  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. <i>International Journal of Epidemiology</i> , 2003, 32, 717-724.	1.9	129
2	Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. <i>Hepatology</i> , 2016, 63, 1205-1212.	7.3	51
3	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	4.4	39
4	Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e607-e614.	4.6	35
5	Coagulation in acutely ill patients with severe chronic liver disease: Insights from thromboelastography. <i>Journal of Critical Care</i> , 2017, 38, 215-224.	2.2	30
6	Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 951-956.	2.8	28
7	Terlipressin: Current and emerging indications in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 591-598.	2.8	21
8	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1314-1322.	3.7	21
9	Epidemiology and outcomes of acute liver failure in Australia. <i>World Journal of Hepatology</i> , 2019, 11, 586-595.	2.0	20
10	Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation. <i>Hepatology</i> , 2014, 60, 2125-2126.	7.3	19
11	Nutraceuticals for the treatment of sarcopenia in chronic liver disease. <i>Clinical Nutrition ESPEN</i> , 2021, 41, 13-22.	1.2	15
12	The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 434-441.	2.8	14
13	Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1368-1375.	1.5	14
14	Efficacy of outpatient continuous terlipressin infusions for hepatorenal syndrome. <i>Hepatology</i> , 2016, 64, 316-318.	7.3	13
15	Continuous terlipressin infusion is associated with improved diet intake and muscle strength in patients awaiting liver transplant. <i>JHEP Reports</i> , 2019, 1, 107-113.	4.9	13
16	Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). <i>BMJ Open</i> , 2015, 5, e008938.	1.9	12
17	Comparison of Thromboelastography and Conventional Coagulation Tests in Patients With Severe Liver Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962092591.	1.7	12
18	Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1309-1317.	1.5	5

#	ARTICLE	IF	CITATIONS
19	Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. <i>BMC Cancer</i> , 2020, 20, 483.	2.6	5
20	Inducible Left Ventricular Outflow Tract Obstruction in Patients Undergoing Liver Transplantation: Prevalence, Predictors, and Association With Cardiovascular Events. <i>Transplantation</i> , 2021, 105, 354-362.	1.0	5
21	Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. <i>Liver Transplantation</i> , 2022, 28, 236-246.	2.4	3
22	The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. <i>Transplantation Direct</i> , 2022, 8, e1345.	1.6	2
23	Letter to the Editor: Rethinking public health measures to reduce liver injury from therapeutic acetaminophen ingestion. <i>Hepatology</i> , 2022, 75, 495-496.	7.3	0